

"EXPRESS MAIL" MAILING LABEL NUMBER
DATE OF DEPOSIT 17 JANUARY 2002.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Blackburn et al. Group Art Unit No.:
Serial No.: Examiner:
Filed: 16 January 2002 Attorney Docket No.: P50438D2
For: ANTICOAGULANT AGENTS USEFUL IN TREATMENT OF THROMBOSIS

PRELIMINARY AMENDMENT

Prior to substantive examination, please amend the above-identified application as follows.

In the specification:

Please insert the following before the first sentence on page 1:
"This application is a divisional of Application Serial No. 09/344,050, filed 25 June 1999, which is a divisional of Application Serial No. 08/783,853, filed 16 January 1997, now U.S. Patent No. 6,005,091, which claims the benefit of U.S. Provisional Application No. 60/010,108, filed 17 January 1996, and U.S. Provisional Application No. 60/029,119, filed 24 October 1996."

In the claims:

Please cancel claims 3-5, 8, 9, and 11-38, without prejudice.

Please amend the claims as follows:

1. (Amended) A method for inhibiting thrombosis in an animal comprising administering an effective dose of an anti-coagulation factor IX/IXa monoclonal antibody.

6. (Amended) The method of claims 1 or 2 wherein the anti-Factor IX monoclonal antibody has the identifying characteristics of SB 249413, SB 249415, SB 249416, SB 2249417, SB 257731 or SB 257732.

7. (Amended) The method of claims 1 or 2 wherein the anti-Factor IX monoclonal antibody has the identifying characteristics of SB 249417.

Add the following new claims:

--39. The method of claim 10 wherein the thrombosis is associated with stroke.

40. The method of claim 10 wherein the thrombosis is associated with sepsis.

41. The method of claim 1 wherein the anti-coagulation Factor IX/IXa antibody binds with an epitope of the Factor IX gla domain.

42. The method of claim 41 wherein the epitope is located within residues 3-11 of Factor IX.

43. The method of claim 42 wherein the antibody has a binding affinity of at least 4 nM.--


Remarks

Claims 1, 2, 6, 7, 10 and 39-43 are pending in this application after entry of this Amendment.

Claim 1 has been amended to more particularly point out and distinctly define the invention. Claims 6 and 7 have been amended to change their dependency from a now-cancelled claim. New claims 39-43 have been added.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captions "**Version with Marking to Show Changes Made.**"

Entry of this amendment is respectfully requested.

Respectfully submitted,

Kirk Baumeister
Attorney for Applicants
Registration No. 33,833

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone: (610) 270-5096
Fax: (610) 270-5073

n:\kb\ptodocs\p50438d2\pmam

"Version with Marking to Show Changes Made."

In the claims:

Claim 1 has been amended as follows:

1. (Amended) A method for inhibiting thrombosis in an animal comprising administering an effective dose of an anti-coagulation factor IX/IXa monoclonal antibody [having self-limiting neutralizing activity].

6. (Amended) The method of [claim 5] claims 1 or 2 wherein

the anti-Factor IX monoclonal antibody has the identifying characteristics of SB 249413, SB 249415, SB 249416, SB 2249417, SB 257731 or SB 257732.

7. (Amended) The method of [claim 5] claims 1 or 2 wherein the

anti-Factor IX monoclonal antibody has the identifying characteristics of SB 249417.

Claims 3-5, 8, 9, and 11-38 were canceled.

New claims 39-43 were added.